LAUSR

1 Lehnhardt A, Karnatz C, Ahlenstiel-Grunow T et al. Clinical and molecular characterization of patients with heterozygous mutations in Wilms tumor suppressor gene 1. Clin. J. Am. Soc. Nephrol. 2015; 10: 825–31. 2 Nagatani K, Hayashi M. [Successful cyclosporin A therapy for diffuse mesangial sclerosis associated with two WT1 mutations]. Jpn. J. Pediatr. Nephrol. 2016;29:39–44 (in Japanese with English abstract). 3 B€uscher AK, Beck BB, Melk A et al. Rapid response to cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 2016; 11: 245–53. 4 Faul C, Donnelly M, Merscher-Gomez S et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 2008; 14: 931–8. 5 Iijima K, Hamahira K, Kobayashi A, Nakamura H, Yoshikawa N. Immunohistochemical analysis of renin activity in chronic cyclosporine nephropathy in childhood nephrotic syndrome. J. Am. Soc. Nephrol. 2000; 11: 2265–71.